Yazar "Mok, T." seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3(Elsevier Science Inc, 2020) Selvaggi, G.; Wakelee, H. A.; Mok, T.; Wu, Y. -L.; Reck, M.; Chiappori, A.; Cicin, I.[Abstract Not Available]Öğe Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.(Elsevier Science Inc, 2021) Selvaggi, G.; Wu, Y.; Wang, Z.; Wu, G.; Poddubskaya, E.; Reck, M.; Mok, T.[Abstract Not Available]
